Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, announced its participation in two upcoming investor conferences in September. The company, which focuses on developing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other diseases involving protein growth factors, will be present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 in New York City, with a fireside chat scheduled for 7:00 a.m. ET.
2. 2024 Wells Fargo Healthcare Conference on September 5 in Boston, where management will engage in one-on-one meetings.
A live webcast of the Morgan Stanley event will be available on Scholar Rock's website, with an archived replay accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK), un'azienda biofarmaceutica in fase avanzata, ha annunciato la sua partecipazione a due prossime conferenze per investitori a settembre. L'azienda, che si concentra sullo sviluppo di trattamenti innovativi per la atrofia muscolare spinale (SMA), disturbi cardiometabolici e altre malattie legate ai fattori di crescita proteici, sarà presente a:
1. 22° Conferenza Annuale Globale della Sanità di Morgan Stanley il 5 settembre a New York City, con un incontro previsto per le 7:00 a.m. ET.
2. Conferenza Sanitaria Wells Fargo 2024 il 5 settembre a Boston, dove la direzione parteciperà a incontri one-to-one.
Una diretta streaming dell'evento di Morgan Stanley sarà disponibile sul sito web di Scholar Rock, con una registrazione archiviata accessibile per circa 90 giorni.
Scholar Rock (NASDAQ: SRRK), una empresa biofarmacéutica en etapa avanzada, anunció su participación en dos conferencias de inversores que se llevarán a cabo en septiembre. La empresa, que se centra en desarrollar tratamientos innovadores para la atrofia muscular espinal (AME), trastornos cardiometabólicos y otras enfermedades relacionadas con los factores de crecimiento proteicos, estará presente en:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley el 5 de septiembre en la ciudad de Nueva York, con una charla programada a las 7:00 a.m. ET.
2. Conferencia de Salud Wells Fargo 2024 el 5 de septiembre en Boston, donde la dirección participará en reuniones uno a uno.
Se dispondrá de una transmisión en vivo del evento de Morgan Stanley en el sitio web de Scholar Rock, con una repetición archivada accesible durante aproximadamente 90 días.
스콜라 록 (NASDAQ: SRRK), 후기 단계의 생물 제약 회사는 9월에 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다. 척수 근육 위축증 (SMA), 심혈관 대사 질환, 그리고 단백질 성장 인자를 포함한 다른 질병 치료제를 개발하는 데 집중하는 이 회사는 다음과 같은 회의에 참석할 예정입니다:
1. 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스가 9월 5일 뉴욕에서 열리며, 오전 7시 ET에 화상 채팅이 예정되어 있습니다.
2. 2024 웰스파고 헬스케어 컨퍼런스가 9월 5일 보스턴에서 열리며, 경영진이 일대일 회의에 참석할 것입니다.
모건 스탠리 행사의 라이브 웨비나는 스콜라 록의 웹사이트에서 배포되며, 약 90일 동안 아카이브된 재방송을 이용할 수 있습니다.
Scholar Rock (NASDAQ: SRRK), une entreprise biopharmaceutique en phase avancée, a annoncé sa participation à deux conférences pour investisseurs à venir en septembre. L'entreprise, qui se concentre sur le développement de traitements innovants pour l'atrophie musculaire spinale (SMA), les troubles cardiométaboliques et d'autres maladies impliquant des facteurs de croissance protéiques, sera présente à :
1. 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley le 5 septembre à New York, avec un chat prévu à 7h00 ET.
2. Conférence de Santé Wells Fargo 2024 le 5 septembre à Boston, où la direction participera à des réunions en tête-à-tête.
Une diffusion en direct de l'événement de Morgan Stanley sera disponible sur le site Web de Scholar Rock, avec une rediffusion archivée accessible pendant environ 90 jours.
Scholar Rock (NASDAQ: SRRK), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September angekündigt. Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für spinale Muskelatrophie (SMA), kardiometabolische Erkrankungen und andere Krankheiten mit Wachstumshormonen konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. 22. Jährliche Globale Gesundheitskonferenz von Morgan Stanley am 5. September in New York City, mit einem Fireside-Chat, der für 7:00 Uhr ET angesetzt ist.
2. Wells Fargo Healthcare-Konferenz 2024 am 5. September in Boston, wo das Management an Einzelgesprächen teilnehmen wird.
Eine Live-Übertragung der Veranstaltung von Morgan Stanley wird auf der Website von Scholar Rock verfügbar sein, mit einer aufgezeichneten Wiederholung, die etwa 90 Tage lang zugänglich ist.
- None.
- None.
-
Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 7:00 a.m. ET on Thursday, September 5 in
New York City . -
2024 Wells Fargo Healthcare Conference: Scholar Rock management will participate in 1x1 meetings on Thursday, September 5 in
Boston .
A live webcast of the Morgan Stanley event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829227012/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-599
Source: Scholar Rock
FAQ
What investor conferences is Scholar Rock (SRRK) attending in September 2023?
Where can I watch the webcast of Scholar Rock's (SRRK) presentation at the Morgan Stanley conference?
What time is Scholar Rock's (SRRK) fireside chat at the Morgan Stanley conference?
What types of diseases does Scholar Rock (SRRK) focus on treating?
